低级别颅底脑膜瘤辅助放疗后的肿瘤控制与颅神经结局
研究纳入接受手术切除后辅助立体定向放射外科治疗的岩斜区、海绵窦区及桥小脑角区脑膜瘤患者,中位随访75个月时90%实现肿瘤控制,10年无进展生存率90%,19%患者颅神经功能改善,10%出现颅神经功能恶化。
要点
- 辅助SRS后中位随访75个月,90%患者实现肿瘤控制。
- 无进展生存率1年99.5%、3年98%、5年95%、10年90%。
- 19%患者颅神经功能改善,10%出现新发或加重颅神经障碍。
核心结论
- 辅助立体定向放射外科可提供有效的肿瘤控制,且新发或加重颅神经障碍的发生率低。
研究设计与样本
- 回顾性分析前瞻性维持数据库中2022例接受Leksell SRS的脑膜瘤患者,筛选出岩斜区43例、海绵窦区94例、桥小脑角区13例术后辅助SRS患者,共150例,均初始即有至少1项颅神经障碍且随访至少12个月。
- SRS时中位年龄54岁(范围22-81岁),因残留肿瘤行SRS者104例(69%),因复发肿瘤者46例(31%)。
- 中位肿瘤体积8.1 cm³(范围0.3-42),中位边缘剂量13 Gy(范围10-20)。
主要发现
- 中位随访75个月时,135例(90%)实现肿瘤控制。
- SRS后无进展生存率1年99.5%、3年98%、5年95%、10年90%。
- 150例中29例(19%)报告颅神经功能改善。
- 15例(10%)出现SRS后颅神经功能恶化,恶化率1年3.5%、3年5.5%、5年7%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the tumor control and cranial nerve (CN) outcomes after adjuvant stereotactic radiosurgery (SRS) for petroclival, cavernous sinus, and cerebellopontine angle meningiomas. METHODS: From our prospectively maintained database of 2022 patients with meningioma who had undergone Leksell SRS during a 30-year interval, we found 43 patients with petroclival, 94 with cavernous sinus, and 13 patients with cerebellopontine angle meningiomas who had undergone adjuvant SRS after surgical resection of the meningioma. The patients included in the present report had had ≥1 CN deficit at the initial presentation and a minimum follow-up period of 12 months. The median age at SRS was 54 years (range, 22-81). SRS was performed for residual tumor in 104 patients (69%) and recurrent tumor in 46 patients (31%). The median tumor volume treated with SRS was 8.1 cm3 (range, 0.3-42), and the median margin dose was 13 Gy (range, 10-20). RESULTS: Tumor control was achieved in 135 patients (90%) at a median follow-up point of 75 months. The progression-free survival rate after SRS was 99.5% at 1 year, 98% at 3 years, 95% at 5 years, and 90% at 10 years. Overall, 29 of the 150 patients (19%) reported improvement in CN function. Deterioration in CN function after SRS developed in 15 patients (10%). The rate of deterioration was 3.5% at 1 year, 5.5% at 3 years, and 7% at 5 years. CONCLUSIONS: Adjuvant SRS provides effective tumor control and a low rate of new or worsening CN deficits.
引用
- Faramand A, Kano H, Niranjan A, et al. Tumor Control and Cranial Nerve Outcomes After Adjuvant Radiosurgery for Low-Grade Skull Base Meningiomas. World Neurosurg. 2019. PMID: 30880202. doi:10.1016/j.wneu.2019.03.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。